/
BHC
$4.85+$0.09 (+1.89%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$1.8B
373M shares
52-week range
$4.57 – $8.69
7% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-25.21
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.38B | $8.60B | $8.03B | $8.43B | $8.12B | $8.76B | $9.63B | $10.45B |
| Cost of revenue | $2.35B | $2.35B | $2.25B | $2.39B | $2.36B | $2.56B | $2.78B | $4.08B |
| Gross profit | $6.03B | $6.25B | $5.78B | $6.04B | $5.76B | $6.20B | $6.84B | $6.36B |
| Gross margin | 71.9% | 72.7% | 72.0% | 71.6% | 70.9% | 70.8% | 71.1% | 60.9% |
| R&D | $442.0M | $516.0M | $485.0M | $473.0M | $530.0M | $604.0M | $634.0M | $640.0M |
| Operating income | −$2.38B | −$203.0M | $676.0M | $450.0M | $454.0M | $963.0M | $1.55B | $2.22B |
| EBITDA | $3.32B | $3.42B | $3.14B | $3.26B | $2.88B | $2.88B | $3.13B | $3.24B |
| Net income | −$4.15B | −$1.78B | −$559.0M | −$948.0M | −$225.0M | −$592.0M | −$46.0M | $159.7M |
| Net margin | -49.5% | -20.7% | -7.0% | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% |
| EPS (diluted) | -11.86 | -5.06 | -1.57 | -2.61 | -0.62 | -1.62 | -0.13 | 0.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10.3B | $4.20 | $4.08–$4.34 | 3 |
| 2027 | $10.3B | $4.03 | $3.81–$4.26 | 3 |
| 2028 | $9.4B | $2.63 | $2.62–$2.65 | 1 |
| 2029 | $9.3B | $2.76 | $2.75–$2.78 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$181.60
Price
$4.85
Implied upside
+3644%
Peer comparison
Bausch Health Companies Inc
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
www.bauschhealth.com- Employees
- 20,300
- IPO / List date
- Mar 31, 1994
- HQ
- QUEBEC, A8
Held by traders on TradeandTell
No one on the platform currently holds BHC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,575,772 | $8.5M |
| Bridgewater Associatesas of 2026-03-31 | 670,366 | $3.6M |
Recent trades on TradeandTell
No one on the platform has traded BHC yet.
